IDEXX Laboratories, Inc.  

(Public, NASDAQ:IDXX)   Watch this stock  
Find more results for Johnny Henderson´┐Ż
156.83
-1.20 (-0.76%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 156.72 - 159.00
52 week 113.49 - 168.51
Open 158.20
Vol / Avg. 284,368.00/387,145.00
Mkt cap 7.39B
P/E 43.99
Div/yield     -
EPS 3.57
Shares 47.13M
Beta 0.81
Inst. own 99%
May 7, 2015
IDEXX Laboratories Inc Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
Apr 23, 2015
Q1 2015 IDEXX Laboratories Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 3, 2015
IDEXX Laboratories Inc at Raymond James Institutional Investors Conference - 10:25AM EST - Add to calendar
Jan 30, 2015
Q4 2014 IDEXX Laboratories Inc Earnings Release
Jan 30, 2015
Q4 2014 IDEXX Laboratories Inc Earnings Call
Jan 15, 2015
IDEXX Laboratories Inc at JPMorgan Healthcare Conference
Dec 12, 2014
IDEXX Laboratories Inc at Bank of America Merrill Lynch Animal and Dental Health Summit
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 7.37% 12.25%
Operating margin 9.89% 17.52%
EBITD margin - 21.48%
Return on average assets 7.78% 13.92%
Return on average equity 60.03% 57.23%
Employees 6,400 -
CDP Score - -

Address

1 Idexx Dr
WESTBROOK, ME 04092-2041
United States - Map
+1-207-5560300 (Phone)
+1-207-5564346 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

IDEXX Laboratories, Inc. (IDEXX) develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The Company operates through four segments: diagnostic and information technology-based products and services for the veterinary market, which it refers to as the Companion Animal Group (CAG), water quality products (Water) and products for livestock and poultry health, which it refer to as Livestock, Poultry and Dairy (LPD) and its OPTI Medical operating segment remains combined and presented with its remaining pharmaceutical product line and its out-licensing arrangements in a segment, which it refers to as Other segment.

Officers and directors

Jonathan W. Ayers Chairman of the Board, President, Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Brian P. McKeon Chief Financial Officer, Executive Vice President, Treasurer
Age: 51
Bio & Compensation  - Reuters
Jay Mazelsky Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Johnny D. Powers Ph.D. Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Michael J. Williams Ph.D. Executive Vice President
Age: 46
Bio & Compensation  - Reuters
Jacqueline L. Studer Corporate Vice President, General Counsel, Secretary
Bio & Compensation  - Reuters
William T. End Lead Independent Director
Age: 66
Bio & Compensation  - Reuters
Sophie V. Vandebroek Ph.D. Director
Age: 52
Bio & Compensation  - Reuters
Thomas Craig Independent Director
Age: 59
Bio & Compensation  - Reuters
Rebecca M. Henderson Ph.D. Independent Director
Age: 53
Bio & Compensation  - Reuters